3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
27
Neoplasm Metastasis
9
Stomach Neoplasms
7
Ovarian Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Sarcoma
2
Salivary Gland Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Advanced Solid Tumor
2
Advanced Breast Cancer
2
Adenocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
4
Surgical Procedures, Operative
3
Iodine-131
3
Iodine-124
3
Biopsy
3
selpercatinib
2
lenvatinib
2
Watchful Waiting
2
Thyrotropin Alfa
2
Therapeutics
2
Nivolumab
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
Cetuximab
2
Biopsy, Fine-Needle
2
trastuzumab deruxtecan
1
trametinib
1
sintilimab
1
sacituzumab govitecan
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
gallium Ga 68 dotatate
1
fludarabine phosphate
1
defactinib
1
dabrafenib
1
cemiplimab
1
brodalumab
1
binimetinib
1
anlotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Thyroid Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled